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Abstract: Prostate cancer (PCa) testing involves a complex individually based decision making
process. It should consider competing risks from other comorbidities when estimating a survival
benefit from the early detection of clinically significant (cs)PCa. We aimed to develop a prediction tool
that provides concrete advice for the general practitioner (GP) on whether to refer a man for further
assessment. We hereto combined the probability of detecting csPCa and the potential overall survival
benefit from early detection and treatment. The PCa detection probabilities were derived from 3616
men enrolled in the Dutch arm of the European Randomized Study of Screening for Prostate Cancer
(ERSPC). Survival estimates were derived from 19,834 men from the Surveillance, Epidemiology, and
End Results (SEER) registry, ERSPC, and Dutch life tables. Treatment benefit was estimated from the
Prostate Cancer Intervention versus Observation Trial (PIVOT, n = 731). The prediction of csPCa
detection was based on prostate-specific antigen (PSA), age, %freePSA, and digital rectal examination
(DRE). The life expectancy (LE) for patients with PCa receiving no treatment was adjusted for age and
Charlson comorbidity index. A negative impact on LE and treatment benefit was found with higher
age and more comorbidity. The proposed integrated approach may support triage at GP practices, as
PCa is a heterogeneous disease in predominantly elderly men.
Keywords: prostate cancer; screening; prostate cancer survival; prediction model; mortality; treatment;
life expectancy
1. Introduction
Prostate-specific antigen- (PSA) based screening for prostate cancer (PCa) can reduce PCa mortality,
as has been demonstrated in a large-scale European randomized screening trial [1]. However, PSA-based
screening also results in the detection of considerable numbers of indolent PCa due to lack of risk
stratification and the random method of sampling. This results in over-diagnosis and overtreatment of
clinically harmless PCa negatively affecting the harm–benefit ratio [2]. Therefore, referral for further
testing should only be applied to patients with high risk of metastasis and cancer-related mortality.
However, this ideal risk stratification is not yet feasible, even with the use of novel techniques such
as imaging and contemporary biomarkers. The U.S. Preventative Services Task Force, European
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Association of Urology (EAU), and American Urological Association (AUA) guidelines recommend
that men aged 55–69 years should be informed about the benefits and the harms of screening, and
PSA testing should be offered only after informed choice [3–5]. For most men, PCa screening starts
with a visit to the general practitioner (GP). It is the GP’s task/challenge to guide men and to identify
men who can benefit from early detection and treatment. To assist (future) patients and physicians
in interpreting the clinical significance of PSA levels, multivariable PCa risk calculators (RC) have
been developed that estimate the probability of detecting (potentially aggressive) PCa if referred for
prostate biopsy. These RCs improve predictions by including other relevant information, such as age
or family history, in addition to PSA levels [6–8]. However, these PCa RCs do not include a patient’s
characteristics, e.g., life expectancy (LE) and long-term effects of treatment. These are relevant factors,
since risk of experiencing harm from a potentially aggressive PCa is likely to be offset, to some extent,
by a reduced LE for older men [9]. To obtain insight in these competing risks, they need to be quantified
and modeled. The aim of this study is to provide a tool suitable for use in primary care that, on the
basis of readily available information, can assess the risk of having a potentially aggressive PCa in the
context of a man’s LE, and in addition, quantifies potential treatment benefit.
2. Materials and Methods
Several aspects should be taken into account in a shared decision making process to refer for a
biopsy: first, an individual’s current risk of having clinically significant PCa (csPCa) [International
Society of Urological Pathology (ISUP) grade ≥2]; second, his LE in the absence of csPCa; third, his LE
in the case of undetected and untreated csPCa; and lastly, how much benefit could be gained from
treatment in the case of csPCa diagnosis? Since there is no single dataset available comprehensive
enough to simultaneously assess these individual probabilities, multiple data sources were used for
the development of the proposed tool. Figure 1 provides an overview of the different prediction
models and their underlying sources. To summarize, the model predicting the presence of csPCa at
the time of biopsy was based on the Dutch arm of the European Randomized Study of Screening for
Prostate Cancer (ERSPC). Estimates on LE of men diagnosed with csPCa receiving no active treatment
were based on the Surveillance, Epidemiology, and End Results (SEER) registry. The benefit of active
treatment was estimated from the Prostate Cancer Intervention versus Observation Trial (PIVOT).
To predict the LE for men with csPCa receiving active treatment, the treatment benefit from the PIVOT
was added to the LE prediction from the SEER. Estimates on LE for men without csPCa were predicted
using data from the Dutch ERSPC. The outcomes of the different prediction models are displayed in an
easy-to-read format that enables evaluation of csPCa risk in the context of a man’s LE and treatment
effect. Final recommendations for GPs formulated as “no referral needed” or “refer to a urologist”
were based on consensus of risk thresholds by the Prostate Cancer United Kingdom Prostate Risk
Working Group (PCUK-RWG) [10], taking into account the probabilities for having csPCa on a current
biopsy (>5–10%), life expectancy (>10–15 years), and treatment benefit (1–2 years additional gain in
overall survival). If the calculated risk is below the lower limit, the advice is not to refer. If the risk is
within range (see Figure 1), the patient’s preferences can be dictated. If calculated risks are above the
upper limit, the patient should definitely be referred. It should be noted that referral to secondary
care is also indicated when multiple criteria are above the given range. Here, the risk of csPCa and
the potential treatment benefit should be leading, even with an LE estimated to be below 10 years.
For example, if a patient would have an elevated risk of having csPCa when biopsied, an estimated LE
of nine years without csPCA, but a potential treatment benefit of three years, he should be referred for
biopsy, and when the suspicion of csPCa is confirmed, he should be actively treated. The analysis for
each prediction model is described in detail below.
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Figure 1. Flowchart of development of prediction model predicting risk of csPCa on current biopsy, 
overall life expectancy, and treatment benefit for each individual patient. LE: life expectancy, csPCa: 
clinically significant prostate cancer. 
The risk of having a biopsy-detectable csPCa is based on 3616 men who received transrectal 
ultrasound-guided sextant biopsies in the first screening round of the Dutch arm of the ERSPC [7]. 
Only variables to which a GP has easy access were included in the analyses, i.e., age at time of biopsy, 
PSA (two log centered), %freePSA (freePSA/total PSA; two log centered), results of the digital rectal 
examination (DRE) including a rough estimate of prostate volume (PV) estimated during DRE (25, 
40, or 60 cc; two log centered [11]), family history, and the International Prostate Symptom Score 
(IPSS). These predictors were combined in a series of logistic regression models in which the 
discriminative ability of each model was assessed. First, the model was fitted to all observations in 
the given set, and the concordance index was calculated. Second, a dataset was formed by 
bootstrapping with 1000 samples in which the model was again developed and then validated based 
on the original data. The difference in performance between the original and the bootstrapped data 
was the estimated “optimism”. The models with the highest concordance index after correction for 
optimism were selected. As the concordance index does not reflect calibration, the Index of Prediction 
Accuracy (IPA) considering both discrimination and calibration was calculated; a higher IPA 
indicated more accurate predictions [12]. The clinical utility of the models was expressed with net 
benefit (NB) by summing the benefits (true positive biopsies) and subtracting the harms (unnecessary 
biopsy). The harms were weighted by a factor related to the relative harm of a missed cancer versus 
unnecessary biopsies [13]. This weighting was derived from the threshold probability for csPCa at 
which a patient would opt for a biopsy (range considered 3–10%) and were displayed in a decision 
curve analysis graph. A model was considered to be clinically useful if its NB was higher than the 
default strategy (biopsy if PSA ≥ 3.0 ng/mL).  
The LE for men with csPCa without receiving treatment was estimated based on the SEER 
program [14]. The SEER consisted of 19,639 men (age ≥65) diagnosed in the period from 1 January 
1992 to 31 December 2005 and 195 men (age <65) diagnosed between 1 January 1971 and 31 December 
1984 [15,16]. The SEER reported overall mortality outcomes for Gleason Score (Gleason Score 5–7 and 
Gleason 8–10), age (55–59, 60–64, 65–69, 70–74, 75+) and Charlson comorbidity index (0, 1, ≥2). These 
survival curves were approximated using a Weibull distribution. To estimate LE for men with 
Fig re 1. Flo chart of evelo ent of re iction o el re icting risk of cs a on c rrent bio sy,
overall life expectancy, and treat ent benefit for each individual patient. LE: life expectancy, csP a:
clinically significant prostate cancer.
The risk of having a biopsy-detectable csPCa is based on 3616 men who received transrectal
ultrasound-guided sextant biopsies in the first screening round of the Dutch arm of the ERSPC [7].
Only variables to which a GP has easy access were included in the analyses, i.e., age at time of biopsy,
PSA (two log centered), %freePSA (freePSA/total PSA; two log centered), results of the digital rectal
examination (DRE) including a rough estimate of prostate volume (PV) estimated during DRE (25, 40,
or 60 cc; two log centered [11]), family history, and the International Prostate Symptom Score (IPSS).
These predictors were combined in a series of logistic regression models in which the discriminative
ability of each model was assessed. First, the model was fitted to all observations in the given set,
and the concordance index was calculated. Second, a dataset was formed by bootstrapping with
1000 samples in which the model was again developed and then validated based on the original data.
The difference in performance between the original and the bootstrapped data was the estimated
“optimism”. The models with the highest concordance index after correction for optimism were
selected. As the concordance index does not reflect calibration, the Index of Prediction Accuracy
(IPA) considering both discrimination and calibration was calculated; a higher IPA indicated more
accurate predictions [12]. The clinical utility of the models was expressed with net benefit (NB)
by summing the benefits (true positive biopsies) and subtracting the harms (unnecessary biopsy).
The harms were weighted by a factor related to the relative harm of a missed cancer versus unnecessary
biopsies [13]. This weighting was derived from the threshold probability for csPCa at which a patient
would opt for a biopsy (range considered 3–10%) and were displayed in a decision curve analysis
graph. A model was considered to be clinically useful if its NB was higher than the default strategy
(biopsy if PSA ≥ 3.0 ng/mL).
The LE for men with csPCa without receiving treatment was estimated based on the SEER
program [14]. The SEER consisted of 19,639 men (age ≥65) diagnosed in the period from 1 January
1992 to 31 December 2005 and 195 men (age <65) diagnosed between 1 January 1971 and 31 December
1984 [15,16]. The SEER reported overall mortality outcomes for Gleason Score (Gleason Score 5–7
and Gleason 8–10), age (55–59, 60–64, 65–69, 70–74, 75+) and Charlson comorbidity index (0, 1, ≥2).
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These survival curves were approximated using a Weibull distribution. To estimate LE for men with
Gleason 3 + 4 or higher (ISUP grade ≥2), the Gleason Score distribution from the Dutch ERSPC was
used to adjust the SEER’s reported Gleason Score distribution [17].
Also, a relative effect of 0.79 on PCa mortality was applied to the pre-PSA era SEER cohort
to include the reduction in PCa mortality by the introduction of PSA [16,18]. The reported SEER’s
outcomes and adjustments were fitted in a model with a Weibull distribution to predict individual LE
for men with csPCa receiving no treatment.
The treatment benefit of csPCa was based on the PIVOT [19]. The PIVOT is a randomized trial
comparing treatment effect of radical prostatectomy versus watchful waiting in 731 men with localized
prostate cancer diagnosed in the era of PSA testing. The relative effect for all-cause mortality for
treatment versus no active treatment was extracted, and the life expectancy for men with csPCa and
treatment were estimated using the survival curves, which were adjusted using the relative treatment
effect from the PIVOT trial. Besides the PIVOT study, other randomized clinical trials comparing
PCa treatment with observation include the Scandinavian Prostate Cancer Group Study Number 4
(SPCG-4) and the Prostate Testing for Cancer and Treatment (ProtecT) trial [20,21]. These trials have
similar long follow-up. A sensitivity analysis was performed to compare the LEs after treatment for
men with csPCa using the relative treatment effects from the PIVOT, SPCG-4, and ProtecT.
The LE for men without csPCa was estimated using data of the Dutch ERSPC [1,22]. In the period
1993–1999, a total of 21,210 men (age 54–74) were randomized to the screening arm; 19,970 men had
a PSA test at the first screening round. We excluded men diagnosed with csPCa in the first round
(n = 313) and men with life-threatening malignancies (n = 410), such as lung cancer, colon cancer, and
leukemia. These patients should not be tested for prostate cancer, since the likelihood that they would
benefit from an early PCa diagnosis is low [23]. Skin cancer was not an exclusion criterion. This led to
a total of 19,247 men available for the prediction of LE for men without csPCa. Survival and follow-up
time in months since time of first visit, survival status (dead or alive), age at visit, and Charlson
comorbidity index were entered in a Weibull distribution model to calculate the LE for an individual
without csPCa. Data for survival status was obtained by linkage with national registries (Central
Bureau for Statistics, 2015). Charlson comorbidity index was missing in 158 cases and was imputed
using multiple imputation with the chained equations procedure and predictive mean matching [24].
As men with a healthy lifestyle are more inclined to participate in screening studies, a healthy screenee
effect may be introduced [25]. Therefore, to generalize the ERSPC data to a general Western population,
the ERSPC LE was adjusted for a potential healthy screenee effect with the World Health Organization
(WHO) Dutch life tables. The relative mortality between the ERSPC and the Dutch life tables was
calculated with a Poisson regression corrected for age and comorbidity [26,27]. This relative mortality
was added to the LE prediction for men without csPCa.
3. Results
For the prediction of having a biopsy-detectable csPCa, a total of 3616 men underwent sextant
biopsies (PSA ≥ 3.0 ng/mL) in the first screening round ERSPC Rotterdam. A total of 313 (9%) csPCa
cases were detected in addition to 572 (16%) indolent PCa cases (ISUP grade 1). Clear differences
between no PCa, indolent PCa, and csPCa were noted for age, PSA, freePSA/total PSA ratio (%freePSA),
prostate volume, and number of abnormal DRE/TRUS (transrectal ultrasound) findings (Table 1).
Family history and IPSS did not differ between groups. The combination of PSA, age, and %freePSA
(further referred to as the “basic model”) was associated with a significant increase in the concordance
index compared to PSA alone (0.810 versus 0.767; p < 0.001), and the IPA was 21%, indicating a useful
prediction model with good discrimination and calibration. The addition of DRE and a rough estimate
of prostate volume to the prediction model increased the concordance index even more [to 0.839
(p < 0.001) and 0.862 (p < 0.001), respectively; Table 2]. Decision curve analysis showed a positive
net benefit for all models compared to the default strategy (biopsy when PSA ≥3.0 ng/mL, Figure S1).
The basic model with a 5% threshold would have a net reduction of 26% (261/1000) biopsies compared
J. Pers. Med. 2019, 9, 19 5 of 10
to the default strategy while not increasing the missed csPCa (Table S1). The basic model was included
in the final prediction tool, as it has a good balance between high predictive accuracy and practical
considerations (i.e., every GP can easily use the basic model).
For men without csPCa, LE was estimated using a Weibull distribution on the ERSPC section
Rotterdam (n = 19,553). The median follow-up was 15 years (interquartile range 12–17). Between 1993
and 2013, 7318 (38%) men died, 172 (2%) of whom died of PCa. The 10-year overall survival rate was
81% (95% CI: 80–81%). A healthy screenee effect with a hazard ratio of 1.6 was found between the
ERSPC screening cohort versus the general population (Table S2).
Table 1. Characteristics of 3616 men with a biopsy stratified to prostate cancer outcome from the
European Randomized Study of Screening for Prostate Cancer (ERSPC).
Characteristics No PCan = 2731 (75%)
Indolent PCa
(GS 3 + 3)
n = 572 (16%)
PCa GS ≥3 + 4
n = 313 (9%)
Age, years, median (IQR) 66 (60–70) 67 (61–70) 68 (64–71)
PSA, ng/mL, median (IQR) 4.0 (2.5–5.7) 5.1 (3.7–7.4) 7.8 (4.8–16.0)
%FreePSA 0.22 (0.17–0.28) 0.17 (0.12–0.24) 0.12 (0.08–0.17)
Prostate volume, mL, median (IQR) 43 (33–57) 37 (29–50) 37 (29–47)
Abnormal DRE, n (%) 836 (31) 236 (41) 207 (66)
Abnormal TRUS, n (%) 795 (29) 226 (40) 208 (66)
Positive family history, n (%) 210 (8) 64 (11) 30 (10)
IPSS, median (IQR) 5 (2–11) 4 (1–9) 4 (1–10)
PCa = prostate cancer, GS = Gleason Score, DRE = digital rectal exam, TRUS = transrectal ultrasound,
PSA = prostate-specific antigen, IQR = interquartile range, IPSS = International Prostate Symptom Score.
Table 2. Concordance index corrected for optimism and index of prediction accuracy (IPA) for
individual and combined predictive performance for each variable of the risk calculator predicting
prostate cancer with Gleason ≥3 + 4 in 3616 men from the ERSPC.
Univariable ConcordanceIndex (95% CI)
IPA
(%) Multivariable
Concordance
Index (95% CI)
IPA
(%)
PSA 0.77 (0.74–0.80) 15.4 PSA + Age 0.77 (0.74–0.80) 15.5
Age 0.59 (0.56–0.62) 0.7 PSA + %FreePSA 0.80 (0.77–0.83) 20.3
%FreePSA 0.78 (0.75–0.81) 11.1 PSA + Age + %FreePSA 0.81 (0.78–0.84) 21.0
DRE 0.67 (0.64–0.70) 3.9 PSA + Age + DRE 0.82 (0.79–0.84) 22.3
Prostate volume 0.60 (0.56–0.63) 0.7 PSA + Age + DRE + %FreePSA 0.84 (0.81–0.86) 26.3
FH 0.51 (0.49–0.52) 0.0 PSA + Age + DRE + %FreePSA + PV 0.86 (0.84–0.88) 28.3
IPSS/AUA 0.52 (0.49–0.56) 0.0 Above + TRUS 0.87 (0.85–0.90) 31.6
TRUS 0.68 (0.65–0.71) 4.5 Above + FH and IPSS/AUA 0.86 (0.84–0.88) 31.6
%FreePSA = FreePSA divided by PSA, AUA = American Urological Association symptom score, PV = prostate
volume, FH = family history.
The estimates of LE in years for men with csPCa receiving no treatment were made on the basis of
age and the Charlson comorbidity index using the SEER data (Figure 2). For men without comorbidity
aged 65, 70, or 75 years, the LE was estimated to be 12.3, 10.9, and 9.7 years, respectively.
The treatment benefit for men with csPCa was estimated as a hazard ratio (HR) of 0.84 (95% CI,
0.70 to 1.01) on all-cause mortality in the PIVOT trial [19]. This overall hazard ratio (0.84) was used to
estimate the absolute treatment benefit. Treatment of csPCa was expected to increase LE with 1.6 years,
1.5 years, and 1.3 years for men without comorbidity aged 65, 70, and 75 years, respectively (Figure 2).
The SPCG-4’s and ProtecT’s HR for death by any cause were 0.74 (95% CI, 0.62–0.87) and 0.93 (95% CI,
0.65–1.35), respectively. In the sensitivity analysis, shorter LE for men with csPCa receiving treatment
was found when the ProtecT’s HR was used, and longer LE was found when using the SPCG-4’s HR,
supplement Table S3.
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Prostate Cancer Intervention versus Observation Trial (PIVOT). The green color indicates a patient 
should be referred to a urologist, red indicates the patient should not be referred. Colors overlap 
because risk of csPCa on a current biopsy should also be weighted. 
The individual risk of having csPCa, the LE, and the potential absolute treatment benefit in terms 
of survival rate were checked against the recommendations and are summarized in an advice for 
referral to secondary care in Figure 3. In this example, a 65-year-old man without comorbidity had a 
PSA level of 4.0 ng/mL and %freePSA of 17%. His current risk of csPCa on biopsy was 9%. The 
patient's life expectancy would be 12.3 years if csPCa was undetected and untreated. If the cancer 
was detected and treated, his life expectancy would increase by 20 months. Here, one would advise 
a referral for further assessment. However, a 75-year-old man with Charlson comorbidity index 2 
with similar PSA and freePSA values would have a very limited absolute benefit of early detection 
and treatment despite a higher risk of having csPCa (15%). The latter man should not be referred to 
a urologist, as his potential benefit from referral would be low.  
Figure 2. Life expectancy in years (y) for patients with clinically significant prostate cancer receiving
no treatment based on Weibull di tribution from the SEER. Secondly, gain in life expectancy (LE)
months ( ) by csPCa treatment ba ed on the elative risk redu tion for all-cause mortality from the
Prostate Cancer Intervention versus Observation Trial (PIVOT). The green color indicates a patient
should be referred o a urologist, red indicates the p tient should not be referred. Color overlap
beca se risk o csPCa n a current biopsy should also be weighted.
The individual risk of having csPCa, the LE, and the potential absolute treatment benefit in terms
of survival rate were checked against the r commendations and re summarized in a advice for
referral to secondary care in Figure 3. In this xa pl , a 65-year-old man without comorbidity had a
PSA level f 4.0 g/mL and %freePSA of 17%. His current risk of csPCa on biopsy was 9%. The patient’s
life exp ctancy would be 12.3 years if csPCa was undetected and untreated. If the cancer was detected
and treated, his life expectancy would increase by 20 months. H r , one would advise a referral for
further assessment. However, a 75-year-old man with Charlson co rbidity index 2 ith similar
PSA and freePSA values would have a v ry limited absolute be efit of early dete tion an treatm nt
despite a higher risk of having csPCa (15%). The latter man should not be referred to a urologist, as his
potential benefit from referral would be low.
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Figure 3. Output of the prediction tool for the general practitioner (GP). Displaying risk of clinically
significant prostate cancer (csPCa; Gleason score ≥3 + 4) on a current biopsy, LE in years with and
without csPCa, treatment benefit in years, and referral advice in two male examples.
4. Discussion
The integrated approach described in this manuscript provides the potential gain in LE when
being diagnosed and treated for csPCa. In current practice, many men are referred with a high PSA for
a prostate biopsy to the urologist, while many have benign prostatic hyperplasia. Prediction tools can
already reduce unnecessary referrals for biopsies [9]. However, many old men are still referred simply
on the basis of having an elevated risk of having a csPCa, while it is unlikely that they will benefit
from detection and treatment of their PCa. The proposed tool can help primary care physicians triage
patients for timely and necessary referral for further assessment, and as such, can aid in reducing
unnecessary testing, over-diagnosis, and subsequent overtreatment. This approach can thus aid in
improving the unfavorable harm–benefit ratio of opportunistic PSA testing [28]. The prediction tool is
easy to use, as it requires only readily accessible information and provides risk percentages supported
by recommendations on how to pursue. It is suitable for Western daily clinical practice, as it has
been developed on well-known, long-term, high quality cohorts, including the SEER, the PIVOT, and
the ERSPC.
Prostate cancer risk calculators including patients’ LEs have been published before [10,29].
However, the calculators lack recommendations and do not include treatment benefit in terms of
overall survival. To estimate treatment benefit in the current prediction tool, PIVOT follow-up data
were used [19]. The PIVOT data show that after nearly 20 years of follow-up surgery, localized PCa was
associated with a lower all-cause or PCa-specific mortality compared to observation. Even with this
long follow-up, the event rate was so low that no statistical significance was reached for the treatment
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effect of 0.84. The confidence interval indicated substantial uncertainty around this effect estimate
(0.70 to 1.01). Other randomized clinical trials comparing PCa treatment with observation include the
SPCG-4 and the ProtecT trial. The SPCG-4 with 29-year follow-up showed that surgery was associated
with longer LE for men with localized PCa [20]. The ProtecT with 10-year follow-up found no clear
differences between surgery, radiation, or active monitoring [21]. The mortality differences across these
three studies may reflect differences in patients’ characteristics, the natural history of PCa, and the
difference in detection and treatment methods. Sensitivity analysis was performed using the different
relative treatment effects from these studies. More treatment benefit, and thus longer LE, was predicted
when the relative treatment effect from the SPCG-4 was used, and shorter LE was predicted when
the relative treatment of the ProtecT was used. Unfortunately, individual treatment benefit based
on patients’ characteristics could not be estimated, as the numbers in all these studies are relatively
small, prohibiting meaningful subgroup analysis [30]. An individual participant data meta-analysis
involving the collection of the original data from the PIVOT, SPCG-4, and ProtecT would improve
quality and reliability of the treatment effect estimation. This would require collaboration between
researchers and take more time and resources than extracting the results from the published reports.
The construction of our model is not without its potential weaknesses. Treatment benefit is based
on 20-year-old information. Our multidimensional prediction tool needs further validation based
on new screening and treatment trail data. It is important to validate the contemporary treatment
effect. Improvements in prostate cancer treatment might positively affect LE. Also, the predictions are
limited to the information that was available at the time of analysis. For example, we did not include
other predictive factors known to affect LE, e.g., marital status, body mass index (BMI), race, and
smoking. The recommendation to refer a man for further assessment is based on consensus, however,
this recommendation should be seen as an aid in the shared decision making process and not as a
replacement. Treatment effect is based on overall treatment effect from the PIVOT, as no statistical
differences in treatment effect between age groups or comorbidity categories were found. However,
this may have been due to insufficient numbers to properly perform subgroup analysis. Although our
prediction model only estimates LE, other outcome measures can influence a decision to refer for
biopsy, e.g., quality of life, disease-free LE, or progression to metastatic disease. These other outcomes
were not available in the datasets but should be considered when referring a patient. The SEER and the
ERSPC data represent different settings (United States versus Europe). This might be a limitation, as the
SEER consists of 15% African American men, while the ERSPC data mainly consist of Caucasian men.
However, the SEER and the ERSPC have minimal selection bias and represent the general Western
daily clinical practice. The field of prostate cancer detection is developing with imaging techniques
such as mpMRI (multi-parametric magnetic resonance imaging) and PET-scans (positron emission
tomography). MpMRI is known to detect more csPCa than TRUS-guided biopsies [31]. Therefore,
the decision path might be improved with the inclusion of mpMRI target biopsies. However, mpMRI
studies include referred men with a high suspicion of csPCa, which is represented by the high PSA
and the high csPCa prevalence rate. Therefore, it is not yet well-established which patients should
undergo an MRI, as the definition of “high risk of having csPCa” for initial men is not properly defined.
Without a proper mpMRI screening trial with a standardized protocol, it is unobtainable to incorporate
the mpMRI workflow in our model. In the future, our model should be validated for the prediction of
csPCa with the inclusion of mpMRI and other novel biomarkers.
Our proposed GP prostate cancer prediction tool uses age, PSA, %freePSA, and comorbidity to
provide recommendations to refer for prostate biopsy. These predictors provide a balance between
predictive accuracy and practical considerations. Higher clinical impact can be achieved using a more
accurate prediction on the risk of having csPCa when including DRE and prostate volume.
5. Conclusions
The estimation of life expectancy, risk of aggressive PCa, and potential benefit of prostate
cancer treatment are the key aspects in the dilemma for the general practitioner and their patients
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regarding whether or not they should be referred for prostate biopsy. The proposed multivariable and
multidimensional prediction tool needs further validation. It can provide valuable insight into the
expected benefit of an early diagnosis of prostate cancer.
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